|1.||Semple, Sean C: 1 article (09/2007)|
|2.||Scarsella, Marco: 1 article (09/2007)|
|3.||Zupi, Gabriella: 1 article (09/2007)|
|4.||Biroccio, Annamaria: 1 article (09/2007)|
|5.||Leonetti, Carlo: 1 article (09/2007)|
|6.||D'Angelo, Carmen: 1 article (09/2007)|
|7.||Leonetti, C: 1 article (06/2001)|
|8.||Zupi, G: 1 article (06/2001)|
|9.||Stringaro, A: 1 article (06/2001)|
|10.||Benassi, B: 1 article (06/2001)|
06/01/2001 - "Animals treated with SALP INX-6295 exhibited a prolonged reduction of c-myc expression, reduced tumor growth and increased mice survival. "
06/01/2001 - "The systemic administration of INX-6295 encapsulated in stabilized antisense lipid particles (SALP INX-6295) improved plasma AUC (area under the plasma concentration-time curve) and initial half-life of free INX-6295, resulting in a significant enhancement in tumor accumulation and improvement in tumor distribution of antisense oligodeoxynucleotides. "
06/01/2001 - "When administered in combination with cisplatin (DDP), SALP INX-6295 produced a complete tumor regression in approximately 30% of treated mice, which persisted for at least 60 days following the first cycle of treatment. "
09/15/2007 - "A marked tumor weight inhibition was observed in PC-3 xenografts after G3139/docetaxel/INX-6295 treatment, with a complete tumor regression being noted in half the mice. "
|1.||Heterologous Transplantation (Xenotransplantation)